|
In our continued quest to provide research resources without delaying the moment when a research tool may be put to use in your laboratory, we are further streamlining our process of transferring NIDDK research tools to academic research institutions. Click here
Mission
|
The mission of the NIDDK Office of Technology Transfer and Development (OTTD) is to facilitate the utilization and further development of innovative technologies within the global scientific community to advance the programmatic goals of the NIDDK, to further scientific knowledge, and to benefit public health. The OTTD strives to achieve its mission by facilitating a) formal basic and clinical research and development partnerships with external organizations; b) the exchange of research materials with the global research community; c) the identification and appropriate protection of intellectual property through patenting and contracts; and d) the promotion of innovative NIDDK technologies to the global scientific community.
|
Overview
As part of its efforts to achieve this Mission, the Office of Technology Transfer and Development for NIDDK facilitates the formation of collaborations and the transfer of materials, information, and data between investigators at NIDDK and investigators at companies, in academia, and in other federal laboratories.
NIH has a strong history and policy of encouraging ease of availability of research materials, including compounds, proteins, antibodies, vectors, plasmids, knock-out and transgenic mice. As a result, we offer the Simple Letter Agreement (SLA) to arrange for many transfers of materials between NIDDK and academia. In some instances, a Materials Transfer Agreement (MTA) will be more appropriate, and NIH offers a model MTA as well. The MTA can be adapted for use with mice and other materials that have additional requirements for transfer. We are pleased to be able to support the research of other investigators with our materials, and are appreciative of receiving such material support from others.
A collaborative clinical trial, and transfer of the drugs needed for clinical use in the trial, can be arranged under a Clinical Trial Agreement (CTA), or in some cases, such as the use of a proprietary, unmarketed compound in a clinical trial performed at NIH, by arrangement of a Cooperative Research and Development Agreement (CRADA) as permitted through U.S. statute. A Materials CRADA (m-CRADA) may also be a mechanism for transferring proprietary materials for non-clinical use from industry to NIDDK.
Confidentiality is protected through provisions in a CTA, m-CRADA or CRADA, once it is signed. When the exchange of information is exploratory to determine the possibility of a collaboration, the confidential information, such as an unpublished method, a compound, or an Investigational Drug Brochure, can be protected from further disclosure by arranging a Confidential Disclosure Agreement (CDA). While a CRADA or a CTA will also address the issue of confidentiality, a CDA will do so preliminary to or in the absence of another agreement.
Last Updated : Sept 04, 2009
|
|
